Evidence map›Paper›PMID 18003890›Full record

ArticleNeuro-oncology2008

Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker.

Daniel Hägerstrand, Anja Smits, Anna Eriksson, Sunna Sigurdardottir, Tommie Olofsson, Magdalena Hartman, Monica Nistér, Hannu Kalimo, Arne Ostman

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. The use of global profiling in biomarker development for gliomas.Brain pathology (Zurich, Switzerland) · 2011
    Review
  3. Review
  4. Inside the human cancer tyrosine phosphatome.Nature reviews. Cancer · 2011
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Daniel HägerstrandDepartment of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, S-171 76 Stockholm, Sweden.
Anja Smits
Anna Eriksson
Sunna Sigurdardottir
Tommie Olofsson
Magdalena Hartman
Monica Nistér
Hannu Kalimo
Arne Ostman
Uppsala University Hospital · SEKarolinska Institutet · SEUppsala University · SEUniversity of Helsinki · FI

Funding

Cancer Research UKWellcome Trust
6 · The paper itself

Abstract

Grade II gliomas are morphologically and clinically heterogeneous tumors for which histopathological typing remains the major tool for clinical classification. To what extent the major histological subtypes - astrocytomas, oligodendrogliomas, and oligoastrocytomas - constitute true biological entities is largely unresolved. Furthermore, morphological classification is often ambiguous and would be facilitated by specific subtype markers. In this study, 23 grade II gliomas were expression-profiled and subjected to hierarchical clustering. All six oligodendrogliomas were grouped together in one of two major clusters; a significant correlation was thus observed between gene expression and histopathological subtype. Supervised analyses were performed to identify genes differentiating oligodendrogliomas from other grade II tumors. In a leave-one-out test using 10 features for classification, 20 out of 23 tumors were correctly classified. Among the most differentially expressed genes was rPTPbeta/zeta. The expression of the rPTP beta/zeta protein in oligodendrogliomas and astrocytomas was further validated by immunohistochemistry in an independent set of tumors. All 11 oligodendrogliomas of this set displayed strong staining. In contrast, neoplastic astrocytes were mostly negative for rPTPbeta/zeta staining. In summary, this study demonstrates a correlation between gene expression pattern and histological subtype in grade II gliomas. Furthermore, the results from the immunohistochemical analyses of rPTPbeta/zeta expression should prompt further evaluation of this protein as a novel oligodendroglioma marker.

Indexed as

AdultBiomarkers, TumorBrain NeoplasmsDiagnosis, DifferentialFemaleGene ExpressionGene Expression ProfilingGliomaHumansImmunohistochemistryMaleMiddle AgedOligodendrogliomaReceptor-Like Protein Tyrosine Phosphatases, Class 5Reverse Transcriptase Polymerase Chain ReactionBiomarkers, TumorReceptor-Like Protein Tyrosine Phosphatases, Class 5

Identifiers

PMID18003890
PMCPMC2600835
OpenAlexW2097842347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.